Barasertib (AZD1152-HQPA)

目录号:S1147 别名: AZD2811, INH-34, Barasertib-HQPA , Defosbarasertib 中文名称:巴拉塞替

仅限科研使用

Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) 是一种高度选择性的Aurora B抑制剂,无细胞试验中IC50为0.37 nM,作用于Aurora B比作用于Aurora A选择性高3700倍左右。

Barasertib (AZD1152-HQPA) Chemical Structure

CAS: 722544-51-6

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1375.46 现货
RMB 976.12 现货
RMB 3169.53 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Barasertib (AZD1152-HQPA)发表文献104篇:

产品安全说明书

Aurora Kinase抑制剂选择性比较

相关Aurora Kinase产品

生物活性

产品描述 Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) 是一种高度选择性的Aurora B抑制剂,无细胞试验中IC50为0.37 nM,作用于Aurora B比作用于Aurora A选择性高3700倍左右。
靶点
Aurora B [1]
(Cell-free assay)
0.37 nM
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP NHr0VIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX6eIkxNTVyMDDuUS=> M3L5UlQ5yqCq MXLJR|UxRTJ3IH7N Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e2OVkoRjJ3Mke3OlU6RC:jPh?=
LNCaP NWfpb5lNSXCxcITvd4l{KEG|c3H5 MX6wMVUxOCCwTR?= NFLDPYo1QMLiaB?= MoPNbY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bEB1cHKxdXfoJINie3Cjc3WtN{B2eHKnZ4XsZZRqd25? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{[1PUc,OjV{N{e2OVk9N2F-
LNCaP MVPGeY5kfGmxbjDBd5NigQ>? NFvGOGo2OCCwTR?= M{DRU|Q5KGh? MlS0bY5lfWOnczDtbYNzd263Y3zlbUB4cXSqIHHu[ZVo\W6rYzDt[YNp[W6rc32= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{[1PUc,OjV{N{e2OVk9N2F-
Ramos MVfGeY5kfGmxbjDBd5NigQ>? NYDkO2FsPTByIH7N NXXEfmFJOC15MjDo NWHwV4ZPcW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl NHuw[4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Daudi  MXvGeY5kfGmxbjDBd5NigQ>? MUG1NFAhdk1? MUmwMVczKGh? NFzE[Y5qdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= NIjNOoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L540 MmPjSpVv[3Srb36gRZN{[Xl? NVXLUJYyPTByIH7N M{fxO|AuPzJiaB?= MUnpcohq[mm2czDBeZJwemFiQjDrbY5ie2V? MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
BJAJ NIPrPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rCeFUxOCCwTR?= M2DFN|AuPzJiaB?= MWLpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Ramos MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITxboI2ODBibl2= NH;0fY8xNTd{IHi= MUnpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Raji NFvZN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXqOVAxKG6P NIrQb2gxNTd{IHi= M33HfIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= NUL6fFZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
Daudi  MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXi1NFAhdk1? NILiVIkxNTd{IHi= NI\vTldqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 M{PYdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L428 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ryN|UxOCCwTR?= NV30NJJHOC15MjDo NYrGTYRqcW6qaXLpeJMh[2WubDDndo94fGh? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
KM-H2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vsdlUxOCCwTR?= Mn7yNE04OiCq MlTybY5pcWKrdIOgZ4VtdCCpcn;3eIg> NVHTV5pRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
HDLM-2 NVfqVWxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HiO|UxOCCwTR?= MWqwMVczKGh? MnrjbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
L450 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTUOVAxKG6P MoPINE04OiCq Ml;VbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NVTLXWZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
BJAJ NWTnUZpmSXCxcITvd4l{KEG|c3H5 MkTyOVAxKG6P NVr4bWZlOC15MjDo M{f2[Ylv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy M3XEelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Ramos NV7sOldySXCxcITvd4l{KEG|c3H5 NFH2SGM2ODBibl2= MlPvNE04OiCq MX\pcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NXT6UI15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
Raji MXfBdI9xfG:|aYOgRZN{[Xl? NYW3VHNrPTByIH7N M2LtPFAuPzJiaB?= M3;5Wolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MoG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Daudi  M3nDTGFxd3C2b4Ppd{BCe3OjeR?= MXy1NFAhdk1? MX6wMVczKGh? MWjpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M{fO[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
L428 NHHRW3JCeG:ydH;zbZMhSXO|YYm= NEnaZ4g2ODBibl2= MnX4NE04OiCq NX7JNHdpcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NHHLbXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
KM-H2 MljERZBweHSxc3nzJGF{e2G7 Mny4OVAxKG6P NWrme2txOC15MjDo MWrpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NXO3UmNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
HDLM-2 M1q0fWFxd3C2b4Ppd{BCe3OjeR?= NIPrUoU2ODBibl2= Ml\5NE04OiCq NUTzVXFXcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NEf3c2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L450 NGn4WJFCeG:ydH;zbZMhSXO|YYm= MX61NFAhdk1? Mmm5NE04OiCq MoLNbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NYPCO5pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
SW620 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrNd4RGSzVyPUGwxtEzNjFibl2= NGDaRm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK0OVA6OCd-MkGyOFUxQTB:L3G+
HCT116 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDFR|UxRTFzwsGzMlMhdk1? NH2xblk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK0OVA6OCd-MkGyOFUxQTB:L3G+
MDA-MB-435 M2PGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG0eoxtOC1zMECwNEBvVQ>? NH3FT|UzNTViZB?= NY\wd5JVTE2VTx?= M4XSOGlEPTB;MUK1JI5O M4nsTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
MDA-MB-468 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLnfXlHOC1zMECwNEBvVQ>? M2n3OVIuPSCm NXq0U2gxTE2VTx?= M3vCdmlEPTB;MUSgcm0> M1nvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
MDA-MB-231 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\1epI2OC1zMECwNEBvVQ>? NXXTV5c5Oi13IHS= M4PnWGROW09? MVXJR|UxRTFyNTDuUS=> MnTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzN{W5NlYoRjJyMUe1PVI3RC:jPh?=
BT474 NXHoU|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDOTGZFOC1zMECwNEBvVQ>? NXPVXHhkOi13IHS= NVTtZW9STE2VTx?= NU\zTXU5UUN3ME24JI5O NEDhV|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-361 NHzCclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3NE0yODByMDDuUS=> NXzZbJRlOi13IHS= MmnRSG1UVw>? NEnxUmhKSzVyPUewJI5O NVnRcXBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
HER18 M3iyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[yblAuOTByMECgcm0> M3XPR|IuPSCm M135WGROW09? MXzJR|UxRTJyIH7N M4PHRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
HER18 M3nJNGFxd3C2b4Ppd{BCe3OjeR?= MXGxNFAhdk1? NV3JOmNROC9{ND:0PEBp M4LQbWROW09? NIDtOmdqdmS3Y3XzJIFxd3C2b4Ppd{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIDveIVvfGmjbB?= Mnn2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzN{W5NlYoRjJyMUe1PVI3RC:jPh?=
MDA-MB-231 NXG5T|JxSXCxcITvd4l{KEG|c3H5 NUfJRmdoOTB3IH7N M1rWeFAwOjRxNEigbC=> MYXEUXNQ M4q1OIlv\HWlZYOgZZBweHSxc3nzJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNicH;0[Y51cWGu NGSxcYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
JHH-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWwMlPjiJNzMECwxsBvVQ>? M4jZflczKGh? NVvEWIo5TUN3ME2xO{41yrFzLkCgcm0> MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
JHH-2 NGnifFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTKNJNSOC5|4pETNVAxOMLibl2= NVnySllSPzJiaB?= NVe2[G9UTUN3ME2yNVgvOMLzMUCuPEBvVQ>? MkTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
JHH-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIix[4ExNjQkgKOxNFAxyqCwTR?= MkT0O|IhcA>? M1vSSGVEPTB;MUW1MlbDuTF4Lkigcm0> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
HuH-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH5eXMxNjQkgKOxNFAxyqCwTR?= M2fDd|czKGh? M1TXfWVEPTB;MkeuN:KyPS5yIH7N NGLydJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
HuH-6 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELuNmcxNjQkgKOxNFAxyqCwTR?= M{jsVFczKGh? MVHFR|UxRTNwN9MxNE43KG6P M2\YVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HuH-7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2wMlPjiJNzMECwxsBvVQ>? NFraNIk4OiCq MVvFR|UxRTZwONMxNE4{KG6P Mk\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HLE M{LhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rQVlAvO+LCk{GwNFDDqG6P MYK3NkBp M3nwV2VEPTB;NEWuPeKyPi52IH7N NYqyOG5uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HLF M3O0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33VUFAvO+LCk{GwNFDDqG6P NFqzVII4OiCq NUfKc2Y2TUN3ME2xNlYvOcLzMUKuNkBvVQ>? M1zSV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
PLC/PRF/5 M1\Vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXVZk{OC5|4pETNVAxOMLibl2= NUL0OIY2PzJiaB?= MnjKSWM2OD15Nj65xtE6Njlibl2= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
SK-Hep1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\uUFAvO+LCk{GwNFDDqG6P NHzFeYw4OiCq M3rjSWVEPTB;MkGuPeKyOS5{IH7N M3TLNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
Hep3B MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHDZYMxNjQkgKOxNFAxyqCwTR?= MnjtO|IhcA>? MUnFR|UxRTdwNtMxNU4zKG6P NHvHZoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
HepG2 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zHblAvO+LCk{GwNFDDqG6P MkfqO|IhcA>? MUjFR|UxRTF2LkhCtVEvPyCwTR?= NYTFUG1iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
Ramos NXPqUnNySXCxcITvd4l{KEG|c3H5 MUeyOU82OC9zMECgcm0> M4H1TlQ5KGh? MV7pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= NYHQN3FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NlMyPjhpPkG5PFI{OTZ6PD;hQi=>
Daudi  Mn:yRZBweHSxc3nzJGF{e2G7 NGnveY4zPS93MD:xNFAhdk1? MnzCOFghcA>? NXzCUG1QcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKGOuZXH2[YQh\m:{bYOgc4YhWEGUUDDhcoQh[2G|cHHz[UA{ NHHGXnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyN|E3QCd-MUm4NlMyPjh:L3G+
BALM-14 M{HyUGFxd3C2b4Ppd{BCe3OjeR?= MVKxNk42NzJ3L{WwJI5O M1nld|Q5KGh? Ml\6bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCz Mn\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MkOxOlgoRjF7OEKzNVY5RC:jPh?=
BALM-27 NVW2cFN4SXCxcITvd4l{KEG|c3H5 Ml;tNVIvPS9{NT:1NEBvVQ>? NV\sNmw3PDhiaB?= MmPtbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCz M4PEPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
NB4 NY\tTVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;LVppFOC5yMT:wMlEwOSEQvF2= NUf6NHhVPDhiaB?= NYDBV5BZcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> MknWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|Nke0PFQoRjF6M{[3OFg1RC:jPh?=
HeLa NILEWI5HfW6ldHnvckBCe3OjeR?= MWKxJJVO NGHtbJozPCCqcoO= NFHEU41KdmirYnn0bY9vKG:oIHH1do9z[SCEIHH1eI9xcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6p MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ6NEW0PUc,OjB4OES1OFk9N2F-
Assay
Methods Test Index PMID
Western blot AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN p53 / p21 / p-p38 / p38 26497213 24782314
Immunofluorescence p21 24782314
Growth inhibition assay Cell viability 26497213

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O

7mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 507.56
化学式

C26H30FN7O3

CAS号 722544-51-6
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03217838 Terminated Drug: AZD2811|Drug: Azacitidine|Drug: Venetoclax Acute Myeloid Leukaemia AstraZeneca November 27 2017 Phase 1|Phase 2
NCT02579226 Completed Drug: AZD2811 Advanced Solid Tumours AstraZeneca October 28 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

回答:
S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.